While Bausch + Lomb has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? This company is expected to post quarterly earnings of $0.49 per share in its upcoming report, which represents a year-over-year change of -27.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.07, ...

Financial Performance - Total revenue for Q2 2024 was $1.216 billion, a 17% increase from $1.035 billion in Q2 2023, with a 20% increase on a constant currency basis[4] - Adjusted EBITDA (non-GAAP) for Q2 2024 was $209 million, up from $179 million in Q2 2023, reflecting a $30 million increase primarily due to higher sales[20] - The company raised its full-year 2024 revenue guidance to $4.700 - $4.800 billion, expecting approximately 16% - 18% constant currency growth[21] - Cash flow from operations improved to $15 million in Q2 2024, compared to a cash outflow of $24 million in Q2 2023, an increase of $39 million[19] - Adjusted net income (non-GAAP) for Q2 2024 was $45 million, down from $65 million in Q2 2023, a decrease of $20 million[18] - Adjusted EPS (non-GAAP) for Q2 2024 was $0.13, down from $0.18 in Q2 2023, representing a decline of 27.78%[45] - Operating income for Q2 2024 was $26 million, down from $43 million in Q2 2023, indicating a decrease of 39.53%[44] - The company reported a net loss of $151 million for Q2 2024, compared to a net loss of $32 million in Q2 2023, reflecting a significant increase in losses[44] Segment Performance - The Pharmaceuticals segment saw a revenue increase of 60%, reaching $310 million compared to $194 million in Q2 2023, driven by the XIIDRA® acquisition and strong launch of MIEBO®[11] - Vision Care segment revenue increased by 8% to $697 million, driven by sales from the dry eye portfolio and daily SiHy lenses[9] - Surgical segment revenue grew by 7% to $209 million, primarily due to increased demand for equipment and consumables[10] Costs and Expenses - The cost of goods sold for Q2 2024 was $482 million, an increase of 15.59% from $417 million in Q2 2023[44] - Research and development expenses for Q2 2024 were $84 million, slightly down from $85 million in Q2 2023[44] - Selling, general and administrative expenses for the three months ended June 30, 2024, were $535 million, up from $417 million in the same period of 2023, representing a 28.3% increase[50] - Interest expense for Q2 2024 was $102 million, significantly higher than $58 million in Q2 2023, reflecting increased borrowing costs[44] Non-GAAP Measures - Adjusted EBITDA (non-GAAP) is used to assess financial performance, focusing on underlying operational results and business performance[33] - The company excludes certain costs from non-GAAP measures, including asset impairments and restructuring costs, to provide a clearer view of operational sustainability[35] - Adjusted net income (non-GAAP) excludes amortization of intangible assets and acquisition-related costs to reflect more accurately the company's financial performance[36] - The company emphasizes the importance of non-GAAP measures for investors, as they provide insights into operating performance and valuation[29] Future Outlook and Risks - Future economic conditions, including inflation and interest rates, are expected to impact revenue, expenses, and margins[25] - Risks associated with the proposed spinoff from Bausch Health Companies Inc. include potential delays and the need for shareholder approvals, which could impact the transaction's completion[25] - The acquisition of XIIDRA® and other ophthalmology assets may not yield expected benefits in a timely manner, and could increase debt levels due to financing[25] - The company expects continued revenue growth driven by new product launches and market expansion strategies[53] - The company is preparing for post-separation operations with transformation initiatives that may lead to restructuring actions and associated costs[35]

Zacks Consensus Estimate The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 31. On the other hand, if they miss, the stock may move lower. This company is expected to post quarterly earnings of $0.13 per share in its upcoming report, which represents a year-over-year change of -27.8%. Estimate Revisions Trend Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revision ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Bausch + Lomb Corporation (Exact name of registrant as specified in its charter) 520 Applewood Crescent, Vaughan, Ontario, Canada L4K 4B4 (Address of Principal Ex ...

Bausch + Lomb Corporation (NYSE:BLCO) Q1 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants George Gadkowski - VP, IR & Business Insights Brent Saunders - Chairman & CEO Sam Eldessouky - EVP & CFO Conference Call Participants Patrick Wood - Morgan Stanley Young Li - Jefferies Robbie Marcus - JPMorgan Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Matt Miksic - Barclays Doug Miehm - RBC Operator Good morning, and welcome to the Bausch + Lomb's First Quarter 2024 Earnings Call. [Opera ...

Other than with respect to GAAP revenue, the company only provides guidance on a non-GAAP basis. The company does not provide a reconciliation of forward-looking Adjusted EBITDA (non-GAAP) to GAAP net income (loss) attributable to Bausch + Lomb Corporation or of forward-looking constant currency revenue growth to reported revenue growth, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. These amounts may be material and, therefore, cou ...

Bausch + Lomb (BLCO) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnin ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the “Board”), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”). With Ms. Ling’s appointment, the Board has been temporarily expanded t ...

Bausch + Lomb Corporation (NYSE:BLCO) Q4 2023 Earnings Conference Call February 21, 2024 8:00 AM ET Company Participants Brent Saunders - Chairman & CEO Sam Eldessouky - EVP & CFO George Gadkowski - VP, IR & Business Insights Conference Call Participants Matt Miksic - Barclays Patrick Wood - Morgan Stanley Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Robbie Marcus - J.P. Morgan Vijay Kumar - Evercore ISI Joanne Wuensch - Citibank Operator Good morning, and welcome to the Bausch + Lomb’s Fourt ...

Bausch + Lomb (BLCO) reported $1.17 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 17.8%. EPS of $0.24 for the same period compares to $0.23 a year ago.The reported revenue represents a surprise of +7.50% over the Zacks Consensus Estimate of $1.09 billion. With the consensus EPS estimate being $0.17, the EPS surprise was +41.18%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall S ...